News

Arkstone Unveils RightDose: Transforming Antimicrobial Management

Arkstone Unveils RightDose: Transforming Antimicrobial Management

Arkstone Introduces RightDose: A Clearer Path for Antimicrobial Dosing

Arkstone, a leader in laboratory infectious disease guidance and antimicrobial stewardship, has launched RightDose—a feature built to simplify how clinicians select and calculate antibiotic doses. Prescribing antibiotics can be complex, and that complexity only grows when caring for children. RightDose steps in with tailored dosing recommendations by age group so providers can move quickly and confidently while keeping treatments safe and effective.

Why Pediatric Dosing Demands Extra Care

Caring for neonates, infants, children, and adolescents isn’t just adult care in smaller doses. Each age group has distinct pharmacokinetic and pharmacodynamic considerations, and the stakes are high when precision matters. Without a single, reliable source to consult, clinicians often bounce between references, guidelines, and calculators—losing time and increasing the chance of error. RightDose brings this information into one place, helping providers find the right dose faster and with less friction.

Pediatric Dosing, Streamlined

RightDose compiles pediatric dosing information and serves it in a way that’s easy to use during real clinical work. Recommendations are tailored by age, and the feature doesn’t stop at pediatrics—its guidance extends to patients across the lifespan. When kidney or liver function should change how a drug is dosed, RightDose includes adjustments for renal and hepatic impairment, further tightening the fit between the patient and the prescription.

One Source for Comprehensive Dosing Guidance

At the core of RightDose is Arkstone’s robust drug database, which consolidates dosing recommendations drawn from trusted sources. Centralizing this information means clinicians can rely on a single, consistent reference instead of piecing together guidance from multiple manuals. The result: clearer, evidence-based direction that supports sound clinical decisions and a safer standard of care.

What Arkstone’s Leaders Are Saying

Dr. Ari Frenkel, Chief Science Officer at Arkstone, shared his enthusiasm regarding RightDose, stating, "This integration into our OneChoice platform marks a significant leap forward in our pursuit of precision medicine. With RightDose, we empower healthcare providers by offering detailed dosing instructions that consider the specific age and health condition of each patient."

Furthermore, Dave Gross, Chief Technology Officer, noted the innovative technology behind RightDose, emphasizing the complexity of its development. "Our sophisticated system matches an extensive array of drug dose combinations with the diverse needs of various age groups. This ensures that healthcare providers receive the most accurate dosing information, which is essential given the absence of a single comprehensive source for this critical data," he said.

Advancing Arkstone’s Work in Infectious Disease Care

The launch of RightDose continues Arkstone’s effort to make antimicrobial management clearer and safer. By pairing practical tools with reliable guidance, the company helps clinicians choose appropriate therapies with fewer workarounds and less guesswork. Better decisions at the point of care lead to better outcomes—patient by patient, day by day.

About Arkstone

Arkstone is focused on addressing antimicrobial resistance and supporting responsible antibiotic use. Using advanced artificial intelligence, Arkstone translates laboratory findings into actionable recommendations, so providers have current, accurate insights available when they need them most.

Frequently Asked Questions

What is RightDose?

RightDose is a feature within Arkstone’s OneChoice platform that delivers tailored antibiotic dosing recommendations. It aligns doses to the patient’s age group and clinical context so providers can prescribe with greater confidence and speed.

How does RightDose improve pediatric care?

It gathers dosing guidance for neonates, infants, children, and adolescents into one place, presenting clear recommendations that fit each age group. That consolidation shortens the search for answers and helps reduce dosing errors in a setting where small mistakes can have outsized effects.

Why does a centralized dosing database matter?

A single, trusted source means clinicians don’t have to cross-check multiple references or assemble dosing rules on the fly. Centralization saves time, reduces variability, and supports safer, more consistent prescribing.

What patient factors does RightDose consider?

Along with age-specific guidance, RightDose includes adjustments for renal and hepatic function. Those refinements help match the dose to the patient’s physiology, improving accuracy and supporting safer treatment plans.

How do healthcare providers benefit from using RightDose?

Providers gain faster access to clear, evidence-based dosing information, which can improve prescribing accuracy, streamline workflows, and support better patient outcomes—without hours spent searching through scattered resources.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 188

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 462

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 268

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 150

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
Quantum Space Joins $185M NASA Lunar Transport Deal

Updated Category News Views 938

Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 87

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 251

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 350

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 490

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 283

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Dining: NYC's Make Food Not Waste Week Unveiled

Updated Category News Views 238

Innovative Dining Movement in NYC More than 20 prominent restaurants in the city are joining forces with Mill, a leading food recycling company, to promote sustainability during the second-annual Make Food Not Waste Restaurant Week. This initiative showcases a commitment to zero food waste, encouraging chefs to practice innovative cooking techniques that minimize waste....

Continue Reading
STAG Industrial Enhances Credit Facility for Future Growth

Updated Category News Views 71

STAG Industrial Extends Credit Flexibility to Support Growth STAG Industrial, Inc. (NYSE: STAG) has refinanced its $1 billion senior unsecured revolving credit facility, reinforcing the company’s access to capital and flexibility. The move keeps STAG well positioned to pursue growth in the industrial real estate market while maintaining a disciplined financial footing....

Continue Reading
Stock Market Analysis: Insight into Current Trends and Highlights

Updated Category News Views 388

Market Overview This week, the financial markets showed a mixed performance, with many analysts pondering the implications of the Federal Reserve's decision to maintain interest rates at 4.25-4.50%. The anticipation around employment numbers added to the cautious sentiment in Wall Street, following disappointing reports that only 73,000 new jobs were created in a month,...

Continue Reading
Rapid7 Unveils Vector Command Advanced to Enhance Security Testing

Updated Category News Views 242

Rapid7 Launches Vector Command Advanced In today's cyber landscape, organizations are increasingly under pressure to demonstrate the effectiveness of their security measures. To address this need, Rapid7, Inc. (NASDAQ: RPD), a pioneering force in threat detection and exposure management, has introduced Vector Command Advanced. This innovative offering enhances their...

Continue Reading
Experience the Elegance of the Jaguar D-Type at Zurich Auction

Updated Category News Views 217

Broad Arrow Auctions Presents an Exceptional Jaguar D-Type In an exciting event for automotive enthusiasts, Broad Arrow Auctions is set to showcase one of the rarest and most stunning cars: a 1956 Jaguar D-Type. This un-raced gem will be a highlight of their inaugural auction in Zurich. With only 71 models ever produced, this particular D-Type, identified as Chassis XKD...

Continue Reading